News
Recent updates from Akiram Therapeutics.
Subscribe here to receive new and press releases to you email.
Akiram Therapeutics announces agreement with leading university hospital on 177Lu-AKIR001 manufacturing for cancer therapy
JANUARY 2024
Akiram Therapeutics has entered into an agreement with Karolinska University Hospital, one of Sweden’s premier medical institutions, for the manufacturing of 177Lu-AKIR001, an antibody-drug conjugate (ADC) radiopharmaceutical designed for treating patients with solid tumors. This agreement marks an important step towards the Phase I first-in-human study, which is planned to start in 2024
Read the press release:
English
Swedish
Akiram Therapeutics strengthens board with drug development expertise
DECEMBER 2023
Akiram Therapeutics is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company’s position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024. Additionally, both Törner and Walberg will be investing in the company.
Read the press release:
English
Swedish
Akiram Therapeutics’ pioneering cancer research backed by SEK 6M from the Erling-Persson Foundation
NOVEMBER 2023
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of aggressive cancers and bolster Akiram’s upcoming Phase I first-in-human human study scheduled for 2024.
Read the press release:
English
Swedish
Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress
SEPTEMBER 2023
Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024.
Read the press release:
English
Swedish
Akiram raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers
JANUARY 2023
The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the drug candidate and for initiating a phase I clinical study.
Read full press release
Read more at Sciety
Read more at Dagens Industri (Swedish)
